Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative

Annie L. Culver, Ira S. Ockene, Raji Balasubramanian, Barbara C. Olendzki, Deidre M. Sepavich, Jean Wactawski-Wende, Jo Ann E. Manson, Yongxia Qiao, Simin Liu, Philip A. Merriam, Catherine Rahilly-Tierny, Fridtjof Thomas, Jeffrey S. Berger, Judith K. Ockene, J. David Curb, Yunsheng Ma

Research output: Contribution to journalArticle

310 Citations (Scopus)

Abstract

Background: This study investigates whether the incidence of new-onset diabetes mellitus (DM) is associated with statin use among postmenopausal women participating in the Women's Health Initiative (WHI). Methods: The WHI recruited 161 808 postmenopausal women aged 50 to 79 years at 40 clinical centers across the United States from 1993 to 1998 with ongoing follow-up. The current analysis includes data through 2005. Statin use was captured at enrollment and year 3. Incident DM status was determined annually from enrollment. Cox proportional hazards models were used to estimate the risk of DM by statin use, with adjustments for propensity score and other potential confounding factors. Subgroup analyses by race/ethnicity, obesity status, and age group were conducted to uncover effect modification. Results: This investigation included 153 840 women without DM and no missing data at baseline. At baseline, 7.04% reported taking statin medication. There were 10 242 incident cases of self-reported D Mover 1 004 466 person-years of follow-up. Statin use at baseline was associated with an increased risk of DM (hazard ratio [HR], 1.71; 95% CI, 1.61-1.83). This association remained after adjusting for other potential confounders (multivariate adjusted HR, 1.48; 95% CI, 1.38-1.59) and was observed for all types of statin medications. Subset analyses evaluating the association of self-reported DM with longitudinal measures of statin use in 125 575 women confirmed these findings. Conclusions: Statin medication use in postmenopausal women is associated with an increased risk for DM. This may be a medication class effect. Further study by statin type and dose may reveal varying risk levels for newonset DM in this population.

Original languageEnglish (US)
Pages (from-to)144-152
Number of pages9
JournalArchives of Internal Medicine
Volume172
Issue number2
DOIs
StatePublished - Jan 23 2012

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Women's Health
Diabetes Mellitus
Propensity Score
Proportional Hazards Models
Age Groups
Obesity

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Culver, A. L., Ockene, I. S., Balasubramanian, R., Olendzki, B. C., Sepavich, D. M., Wactawski-Wende, J., ... Ma, Y. (2012). Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Archives of Internal Medicine, 172(2), 144-152. https://doi.org/10.1001/archinternmed.2011.625

Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. / Culver, Annie L.; Ockene, Ira S.; Balasubramanian, Raji; Olendzki, Barbara C.; Sepavich, Deidre M.; Wactawski-Wende, Jean; Manson, Jo Ann E.; Qiao, Yongxia; Liu, Simin; Merriam, Philip A.; Rahilly-Tierny, Catherine; Thomas, Fridtjof; Berger, Jeffrey S.; Ockene, Judith K.; Curb, J. David; Ma, Yunsheng.

In: Archives of Internal Medicine, Vol. 172, No. 2, 23.01.2012, p. 144-152.

Research output: Contribution to journalArticle

Culver, AL, Ockene, IS, Balasubramanian, R, Olendzki, BC, Sepavich, DM, Wactawski-Wende, J, Manson, JAE, Qiao, Y, Liu, S, Merriam, PA, Rahilly-Tierny, C, Thomas, F, Berger, JS, Ockene, JK, Curb, JD & Ma, Y 2012, 'Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative', Archives of Internal Medicine, vol. 172, no. 2, pp. 144-152. https://doi.org/10.1001/archinternmed.2011.625
Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Archives of Internal Medicine. 2012 Jan 23;172(2):144-152. https://doi.org/10.1001/archinternmed.2011.625
Culver, Annie L. ; Ockene, Ira S. ; Balasubramanian, Raji ; Olendzki, Barbara C. ; Sepavich, Deidre M. ; Wactawski-Wende, Jean ; Manson, Jo Ann E. ; Qiao, Yongxia ; Liu, Simin ; Merriam, Philip A. ; Rahilly-Tierny, Catherine ; Thomas, Fridtjof ; Berger, Jeffrey S. ; Ockene, Judith K. ; Curb, J. David ; Ma, Yunsheng. / Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. In: Archives of Internal Medicine. 2012 ; Vol. 172, No. 2. pp. 144-152.
@article{ee67e777817c434fbd2d05d6f60a508d,
title = "Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative",
abstract = "Background: This study investigates whether the incidence of new-onset diabetes mellitus (DM) is associated with statin use among postmenopausal women participating in the Women's Health Initiative (WHI). Methods: The WHI recruited 161 808 postmenopausal women aged 50 to 79 years at 40 clinical centers across the United States from 1993 to 1998 with ongoing follow-up. The current analysis includes data through 2005. Statin use was captured at enrollment and year 3. Incident DM status was determined annually from enrollment. Cox proportional hazards models were used to estimate the risk of DM by statin use, with adjustments for propensity score and other potential confounding factors. Subgroup analyses by race/ethnicity, obesity status, and age group were conducted to uncover effect modification. Results: This investigation included 153 840 women without DM and no missing data at baseline. At baseline, 7.04{\%} reported taking statin medication. There were 10 242 incident cases of self-reported D Mover 1 004 466 person-years of follow-up. Statin use at baseline was associated with an increased risk of DM (hazard ratio [HR], 1.71; 95{\%} CI, 1.61-1.83). This association remained after adjusting for other potential confounders (multivariate adjusted HR, 1.48; 95{\%} CI, 1.38-1.59) and was observed for all types of statin medications. Subset analyses evaluating the association of self-reported DM with longitudinal measures of statin use in 125 575 women confirmed these findings. Conclusions: Statin medication use in postmenopausal women is associated with an increased risk for DM. This may be a medication class effect. Further study by statin type and dose may reveal varying risk levels for newonset DM in this population.",
author = "Culver, {Annie L.} and Ockene, {Ira S.} and Raji Balasubramanian and Olendzki, {Barbara C.} and Sepavich, {Deidre M.} and Jean Wactawski-Wende and Manson, {Jo Ann E.} and Yongxia Qiao and Simin Liu and Merriam, {Philip A.} and Catherine Rahilly-Tierny and Fridtjof Thomas and Berger, {Jeffrey S.} and Ockene, {Judith K.} and Curb, {J. David} and Yunsheng Ma",
year = "2012",
month = "1",
day = "23",
doi = "10.1001/archinternmed.2011.625",
language = "English (US)",
volume = "172",
pages = "144--152",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative

AU - Culver, Annie L.

AU - Ockene, Ira S.

AU - Balasubramanian, Raji

AU - Olendzki, Barbara C.

AU - Sepavich, Deidre M.

AU - Wactawski-Wende, Jean

AU - Manson, Jo Ann E.

AU - Qiao, Yongxia

AU - Liu, Simin

AU - Merriam, Philip A.

AU - Rahilly-Tierny, Catherine

AU - Thomas, Fridtjof

AU - Berger, Jeffrey S.

AU - Ockene, Judith K.

AU - Curb, J. David

AU - Ma, Yunsheng

PY - 2012/1/23

Y1 - 2012/1/23

N2 - Background: This study investigates whether the incidence of new-onset diabetes mellitus (DM) is associated with statin use among postmenopausal women participating in the Women's Health Initiative (WHI). Methods: The WHI recruited 161 808 postmenopausal women aged 50 to 79 years at 40 clinical centers across the United States from 1993 to 1998 with ongoing follow-up. The current analysis includes data through 2005. Statin use was captured at enrollment and year 3. Incident DM status was determined annually from enrollment. Cox proportional hazards models were used to estimate the risk of DM by statin use, with adjustments for propensity score and other potential confounding factors. Subgroup analyses by race/ethnicity, obesity status, and age group were conducted to uncover effect modification. Results: This investigation included 153 840 women without DM and no missing data at baseline. At baseline, 7.04% reported taking statin medication. There were 10 242 incident cases of self-reported D Mover 1 004 466 person-years of follow-up. Statin use at baseline was associated with an increased risk of DM (hazard ratio [HR], 1.71; 95% CI, 1.61-1.83). This association remained after adjusting for other potential confounders (multivariate adjusted HR, 1.48; 95% CI, 1.38-1.59) and was observed for all types of statin medications. Subset analyses evaluating the association of self-reported DM with longitudinal measures of statin use in 125 575 women confirmed these findings. Conclusions: Statin medication use in postmenopausal women is associated with an increased risk for DM. This may be a medication class effect. Further study by statin type and dose may reveal varying risk levels for newonset DM in this population.

AB - Background: This study investigates whether the incidence of new-onset diabetes mellitus (DM) is associated with statin use among postmenopausal women participating in the Women's Health Initiative (WHI). Methods: The WHI recruited 161 808 postmenopausal women aged 50 to 79 years at 40 clinical centers across the United States from 1993 to 1998 with ongoing follow-up. The current analysis includes data through 2005. Statin use was captured at enrollment and year 3. Incident DM status was determined annually from enrollment. Cox proportional hazards models were used to estimate the risk of DM by statin use, with adjustments for propensity score and other potential confounding factors. Subgroup analyses by race/ethnicity, obesity status, and age group were conducted to uncover effect modification. Results: This investigation included 153 840 women without DM and no missing data at baseline. At baseline, 7.04% reported taking statin medication. There were 10 242 incident cases of self-reported D Mover 1 004 466 person-years of follow-up. Statin use at baseline was associated with an increased risk of DM (hazard ratio [HR], 1.71; 95% CI, 1.61-1.83). This association remained after adjusting for other potential confounders (multivariate adjusted HR, 1.48; 95% CI, 1.38-1.59) and was observed for all types of statin medications. Subset analyses evaluating the association of self-reported DM with longitudinal measures of statin use in 125 575 women confirmed these findings. Conclusions: Statin medication use in postmenopausal women is associated with an increased risk for DM. This may be a medication class effect. Further study by statin type and dose may reveal varying risk levels for newonset DM in this population.

UR - http://www.scopus.com/inward/record.url?scp=84862908066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862908066&partnerID=8YFLogxK

U2 - 10.1001/archinternmed.2011.625

DO - 10.1001/archinternmed.2011.625

M3 - Article

VL - 172

SP - 144

EP - 152

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 2

ER -